CUPR · Cuprina Holdings (Cayman) LTD · Financials

$2.25 -0.17 (-7.02%) At close · Oct 5

Market Cap

$14.95M

7.00M

Volume · Oct 5 43.43K Avg daily vol (3M) 95.09K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Diluted EPS

-$142.00 -178.2%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2025	FY2024	FY2023	FY2022
EPS (Basic) USD/shares	—	—	—	-$142.00	-$51.04	—	—
EPS (Diluted) USD/shares	—	—	—	-$142.00	-$51.04	—	—
Shares Outstanding (Basic Avg) shares	+4.4%	—	—	2.56M	2.25M	2.25M	2.25M
Shares Outstanding (Diluted Avg) shares	+4.4%	—	—	2.56M	2.25M	2.25M	2.25M

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Long-term debt, including current maturities	2025-12-31	SGD 164,929	20-F filed 2026-04-27
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of long-term debt SGD 38,728 Noncurrent debt carrying amount SGD 126,201
Long-term debt, including current maturities	2025-12-31	USD 128,220	20-F filed 2026-04-27
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of long-term debt USD 30,108 Noncurrent debt carrying amount USD 98,112
Operating lease liabilities	2025-12-31	SGD 317,790	20-F filed 2026-04-27
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities SGD 110,233 Noncurrent operating lease liabilities SGD 207,557
Operating lease liabilities	2025-12-31	USD 247,057	20-F filed 2026-04-27
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 85,698 Noncurrent operating lease liabilities USD 161,359

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 0.76×

EV/EBIT

—

P/E (TTM)

—

Peer medians compare against the 13 similar-size Medical Instruments & Supplies companies (of 47 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (SGD)

Component	FY2025	FY2024	FY2023	FY2022
Maggot Debridement Therapy Product	44,204	34,417	78,957	56,599
Cosmeceutical Product	5,690	13,904	21,816	—

Key facts CIK 1995704 CUSIP G2592E110 Visit website Investor relations